News & Updates

Show Multimedia Only
Lipoprotein(a) molar concentrations help inform cardiovascular risk

Lipoprotein(a) molar concentrations help inform cardiovascular risk

19 Feb 2022

The risk of coronary artery disease (CAD) can be predicted by a single accurate measurement of lipoprotein(a) molar concentration if therapies substantially altering lipoprotein(a) are not present, suggests a recent study.

Lipoprotein(a) molar concentrations help inform cardiovascular risk

19 Feb 2022
Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis

Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis

19 Feb 2022

Hospitalization is warranted in one in five patients with new-onset systemic lupus erythematosus (SLE) manifest disease presentations, according to a recent study. Of note, diagnosis has been delayed in nearly 20 percent of patients.

Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis

19 Feb 2022
Edoxaban effectively keeps D-dimer low in patients with NVAF, AHF

Edoxaban effectively keeps D-dimer low in patients with NVAF, AHF

19 Feb 2022
Genetically elevated FT4 levels tied to higher age-related macular degeneration risk

Genetically elevated FT4 levels tied to higher age-related macular degeneration risk

19 Feb 2022
Stroke risk elevated first 3 days post–COVID-19 diagnosis

Stroke risk elevated first 3 days post–COVID-19 diagnosis

18 Feb 2022 byRoshini Claire Anthony

Older patients with COVID-19 may have an increased risk of being hospitalized for acute ischaemic stroke (AIS), particularly in the first 3 days following their COVID-19 diagnosis, according to a study presented at ISC 2022.

Stroke risk elevated first 3 days post–COVID-19 diagnosis

18 Feb 2022
Ixazomib dexamethasone a new treatment in the arsenal against RRMM

Ixazomib dexamethasone a new treatment in the arsenal against RRMM

18 Feb 2022

In heavily pretreated, lenalidomide-refractory patients with relapsed-refractory multiple myeloma (RRMM) and prior exposure to proteasome inhibitors, ixazomib dexamethasone may be an effective and tolerable treatment approach, leading to comparable health-related quality of life outcomes as pomalidomide-dexamethasone, a recent study has found.

Ixazomib dexamethasone a new treatment in the arsenal against RRMM

18 Feb 2022